SYNB1618 + Placebo
Phase 1/2Completed 1 views this week 0 watching💤 Quiet
Interest: 22/100
22
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Phenylketonuria
Conditions
Phenylketonuria, Healthy
Trial Timeline
Apr 17, 2018 → Jun 21, 2019
NCT ID
NCT03516487About SYNB1618 + Placebo
SYNB1618 + Placebo is a phase 1/2 stage product being developed by Synlogic for Phenylketonuria. The current trial status is completed. This product is registered under clinical trial identifier NCT03516487. Target conditions include Phenylketonuria, Healthy.
What happened to similar drugs?
7 of 20 similar drugs in Phenylketonuria were approved
Approved (7) Terminated (1) Active (12)
Hype Score Breakdown
Clinical
9
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03516487 | Phase 1/2 | Completed |
Competing Products
20 competing products in Phenylketonuria
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| mRNA-3210 | Moderna | Phase 2 | 0 |
| SYNB1934v1 + Placebo | Synlogic | Phase 3 | 22 |
| SYNB1618 + SYNB1934 | Synlogic | Phase 2 | 25 |
| Kuvan® | Merck | Phase 3 | 40 |
| Kuvan® | Merck | Approved | 43 |
| SAR444836 | Sanofi | Phase 1/2 | 36 |
| Kuvan | BioMarin Pharmaceutical | Pre-clinical | 15 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 32 |
| rAvPAL-PEG | BioMarin Pharmaceutical | Phase 2 | 32 |
| Sapropterin (Kuvan) | BioMarin Pharmaceutical | Pre-clinical | 23 |
| BMN 165 (rAvPAL-PEG) | BioMarin Pharmaceutical | Phase 2 | 32 |
| BMN 307 | BioMarin Pharmaceutical | Phase 1/2 | 33 |
| Sapropterin | BioMarin Pharmaceutical | Pre-clinical | 23 |
| Sapropterin dihydrochloride + Placebo | BioMarin Pharmaceutical | Phase 3 | 37 |
| BMN165 20mg/day + BMN165 40mg/day + Placebo | BioMarin Pharmaceutical | Phase 3 | 37 |
| sapropterin dihydrochloride | BioMarin Pharmaceutical | Phase 3 | 37 |
| saproterin dihydrochloride | BioMarin Pharmaceutical | Approved | 40 |
| sapropterin dihydrochloride + Moxifloxacin + Moxifloxacin placebo | BioMarin Pharmaceutical | Phase 1 | 26 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 30 |
| Pegvaliase | BioMarin Pharmaceutical | Pre-clinical | 23 |